Concomitant medications and circulating tumor cells: friends or foes?

Abstract

The use of concomitant medications by patients with cancer is observed almost globally; however, little attention has been paid to this topic in the medical literature. Most clinical studies do not describe the type and duration of drugs used at the time of inclusion and during treatment or how these drugs may affect the experimental and/or standard therapy. Even less information has been published on the potential interaction between concomitant medications and tumor biomarkers. However, we do know that concomitant drugs can complicate cancer clinical trials and biomarker development, thus contributing to their interaction, leading to side effects, and resulting in suboptimal adherence to anticancer treatment. On the basis of these premises and moving from the study by Jurisova et al., which reported the effect of commonly used drugs on the prognosis of women with breast cancer and the detection of circulating tumor cells (CTCs), we comment on the role of CTCs as an emerging diagnostic and prognostic tool for breast cancer. We also report the known and hypothesized mechanisms of CTC interplay with other tumor and blood components, possibly modulated by widespread drugs, including over-the-counter compounds, and discuss the possible implications of commonly used concomitant medications on CTC detection and clearance. After considering all these points, it is conceivable that concomitant drugs are not necessarily a problem, but on the contrary, their virtuous mechanisms can be exploited to reduce tumor spread and enhance the effect of anticancer therapies.

Keywords

Breast cancer / concomitant medications / circulating tumor cells

References

[1] Alix-Panabières C.Liquid biopsy: from discovery to clinical application.Cancer Discov2021;11:858-73

[2] Allard WJ,Miller MC.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases.Clin Cancer Res2004;15:6897-904

[3] Keller L.Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells.Nat Rev Cancer2019;19:553-67

[4] Jurisova S,Minarik G.Circulating tumor cells and drug history in primary breast cancer patients.Cancer Drug Resist2020;3:98-109 PMCID:PMC9094054

[5] Riechelmann RP.Drug interactions in oncology: How common are they?.Ann Oncol2009;20:1907-12

[6] Borad MJ,Babiker HM.The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.J Cancer2012;3:345-53 PMCID:PMC3434362

[7] European Medicines Agency; Science Medicines. Healthich E6 (R2) good clinical practice-scientific guideline. Available from: https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice [Last accessed on 4 Jan 2023]

[8] Bednarz-Knoll N,Pantel K.Plasticity of disseminating cancer cells in patients with epithelial malignancies.Cancer Metastasis Rev2012;31:673-87

[9] Fina E,Motta R.Did circulating tumor cells tell us all they could?.Int J Biol Markers2015;30:e429-33

[10] Yu M,Wittner BS.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.Science2013;339:580-4

[11] Gazzaniga P,Gradilone A.Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero.Ann Oncol2011;22:1929-30

[12] Vetter M,Szczerba BM.Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.Breast Cancer Res2018;20:141 PMCID:PMC6247738

[13] Sørlie T,Tibshirani R.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA2001;98:10869-74 PMCID:PMC58566

[14] Ganz PA,Weltzien EK,Cole SW.Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.Breast Cancer Res Treat2011;129:549-56 PMCID:PMC3145014

[15] Chae YK,Lei X.Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes.J Cancer2013;4:549-56 PMCID:PMC3753529

[16] Shimizu T,Chiba S.VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts.Cardiovasc Res2003;58:203-12

[17] Li J,Wun B,King MR.Genetic engineering of platelets to neutralize circulating tumor cells.J Control Release2016;228:38-47 PMCID:PMC4828270

[18] Lou XL,Deng H.Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review).Biomed Rep2014;2:331-4 PMCID:PMC3990215

[19] Willecke-Hochmuth R,Drevs J.Treatment of advanced solid tumours with NSAIDs: correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging.Oncol Lett2016;12:1711-6 PMCID:PMC4997972

[20] Sprouse ML,Boral D.PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling.Int J Mol Sci2019;20:1916 PMCID:PMC6514876

[21] Wculek SK.Neutrophils support lung colonization of metastasis-initiating breast cancer cells.Nature2015;528:413-7 PMCID:PMC4700594

[22] Gener P,Xandri-Monje H.Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells.Nanomedicine2020;24:102106

[23] Fuloria S,Chandel A.A comprehensive review on the therapeutic potential of curcuma longa linn. In relation to its major active constituent curcumin.Front Pharmacol2022;13:820806 PMCID:PMC8990857

[24] Aceto N,Miyamoto DT.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.Cell2014;158:1110-22 PMCID:PMC4149753

[25] Gkountela S,Szczerba BM.Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding.Cell2019;176:98-112.e14 PMCID:PMC6363966